Norgine Completes Acquisition of Theravia
Deal News | Aug 14, 2025 | PR Newswire Cision Norgine
Norgine, a specialty pharmaceutical and consumer healthcare company, has successfully completed the acquisition of Theravia, a pharmaceutical company that specializes in therapies for patients with rare and debilitating conditions. This acquisition is part of Norgine's strategy to expand its portfolio of rare disease medications and deliver significant improvements for patients with high unmet medical needs. The company has announced the initiation of a structured integration process for aligning operations, systems, and teams. Norgine, which has over €550 million in annual revenues, aims to extend the reach of Theravia's medications across Europe, Australia, and New Zealand, integrating its commercial and scientific capabilities to improve delivery and accessibility of these critical treatments. With this acquisition, Theravia is now a wholly-owned subsidiary of Norgine.
Sectors
- Pharmaceuticals
- Healthcare
Geography
- Europe – Norgine's core market, where it plans to expand the distribution of Theravia's medicines.
- Australia – Norgine's core market in the Southern Hemisphere, important for extending Theravia's medicine reach.
- New Zealand – Included in Norgine's targeted area for the distribution of acquired therapies from Theravia.
- France – The announcement of the acquisition was made in Paris, underlining France as a key geographic location for this transaction.
Industry
- Pharmaceuticals – The article centers around the acquisition of Theravia, a company specializing in rare disease therapies, highlighting its significance in the pharmaceuticals industry.
- Healthcare – Norgine's focus on delivering life-changing medicines and improving patient care places this transaction within the broader scope of the healthcare sector.
Financials
- €550 million – Norgine's annual revenue, showcasing its financial capacity for acquisitions.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Norgine | Acquirer | Company | A specialty pharmaceutical and consumer healthcare company with a focus on providing transformative medicines. |
| Theravia | Target Company | Company | An international pharmaceutical company specializing in therapies for rare and debilitating conditions. |
| Janneke van der Kamp | Chief Executive Officer | Person | CEO of Norgine, commenting on the strategic importance of the acquisition. |
| Annabel Cowper | Media Contact | Person | Responsible for media relations at Norgine. |